GVHD: A Continuing Barrier to the Safety of Allogeneic Transplantation

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 1 SUPPL., 2009, Pages 162-168

  Reddy, Pavan ^a   Arora, Mukta ^a   Guimond, Martin ^a   Mackall, Crystal L ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BECLOMETASONE; CALCINEURIN INHIBITOR; CLOFAZIMINE; CYCLOSPORIN A; DACLIZUMAB; ETANERCEPT; ETRETINATE; HYDROXYCHLOROQUINE; INTERLEUKIN 2; INTERLEUKIN 7; KERATINOCYTE GROWTH FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PLACEBO; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT VERSUS HOST DISEASE; ADVERSE DRUG REACTION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE DISEASE; BYSTANDER EFFECT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CONSTIPATION; CYTOKINE PRODUCTION; CYTOPENIA; CYTOTOXIC T LYMPHOCYTE; DRUG ERUPTION; DRUG THERAPY; DRUG WITHDRAWAL; ETIOLOGY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION PREVENTION; KIDNEY DYSFUNCTION; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTOPENIA; NATURAL KILLER T CELL; NEURITIS; NEUTROPENIA; NONHUMAN; PATHOLOGY; PATHOPHYSIOLOGY; REGULATORY T LYMPHOCYTE; RETINA DISEASE; REVIEW; SALVAGE THERAPY; SCLERODERMA; SEDATION; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADVERSE EFFECTS; ANTIGEN-PRESENTING CELLS; DRUG THERAPY; ETIOLOGY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNE SYSTEM; LYMPHOCYTE ACTIVATION; PATHOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 64749100146     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.10.014     Document Type: Article

References (56)

1. Welniak L.A., Blazar B.R., and Murphy W.J. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 25 (2007) 139-170
2. Ferrara J.L., and Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 43 (2006) 3-10
3. Hill G.R., and Ferrara J.L. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95 (2000) 2754-2759
4. Murai M., Yoneyama H., Ezaki T., et al. Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol 4 (2003) 154-160
5. Anderson B.E., Taylor P.A., McNiff J.M., et al. Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells. Blood 111 (2008) 5242-5251
6. Sorror M.L., Maris B., Storer B.B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 104 (2004) 961
7. Sato K., Yamashita N., Baba M., and Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 18 (2003) 367-379
8. Shlomchik W.D. Graft-versus-host disease. Nat Rev Immunol 7 (2007) 340-352
9. MacDonald K.P., Rowe V., Clouston A.D., et al. Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. J Immunol 174 (2005) 1841-1850
10. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371 (2008) 1579-1586
11. Holler E., Rogler G., Brenmoehl J., et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 107 (2006) 4189-4193
12. Granell M., Urbano-Ispizua A., Pons A., et al. Common variants in NLRP2 and NLRP3 genes are strong prognostic factors for the outcome of HLA-identical sibling allogeneic stem cell transplantation. Blood (2008) in press
13. Dustin M.L. Role of adhesion molecules in activation signaling in T lymphocytes. J Clin Immunol 21 (2001) 258-263
14. Korngold R., and Sprent J. Features of T cells causing H-2-restricted lethal graft-vs.-host disease across minor histocompatibility barriers. J Exp Med 155 (1982) 872-883
15. Zhang Y., Joe G., Hexner E., Zhu J., and Emerson S.G. Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat Med 11 (2005) 1299-1305
16. Blazar B.R., and Taylor P.A. Regulatory T cells. Biol Blood Marrow Transplant 11 (2005) 46-49
17. Zeng D., Lewis D., Dejbakhsh-Jones S., et al. Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J Exp Med 189 (1999) 1073-1081
18. Lowsky R., Takahashi T., Liu Y.P., et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 353 (2005) 1321-1331
19. Ratanatharathorn V., Nash R.A., Przepiorka D., et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92 (1998) 2303-2314
20. Zeiser R., Nguyen V.H., Beilhack A., et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 108 (2006) 390-399
21. Ferrara J.L., and Deeg H.J. Graft-versus-host disease. N Engl J Med 324 (1991) 667-674
22. van den Brink M.R., and Burakoff S.J. Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol 2 (2002) 273-281
23. Wysocki C.A., Panoskaltsis-Mortari A., Blazar B.R., and Serody J.S. Leukocyte migration and graft-versus-host disease. Blood 105 (2005) 4191-4199
24. Chakraverty R., Cote D., Buchli J., et al. An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J Exp Med 203 (2006) 2021-2031
25. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 (2004) 987-995
26. Baird K., and Pavletic S.Z. Chronic graft versus host disease. Curr Opin Hematol 13 (2006) 426-435
27. Arora M., Burns L.J., Davies S.M., et al. Chronic graft-versus-host disease: a prospective cohort study. Biol Blood Marrow Transplant 9 (2003) 38-45
28. Koc S., Leisenring W., Flowers M.E., et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 100 (2002) 48-51
29. Sullivan K.M., Witherspoon R.P., Storb R., et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 72 (1988) 555-561
30. Baudard M., Vincent A., Moreau P., Kergueris M.F., Harousseau J.L., and Milpied N. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant 30 (2002) 287-295
31. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108 (2006) 756-762
32. Couriel D.R., Saliba R., Escalon M.P., et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 130 (2005) 409-417
33. Couriel D.R., Hosing C., Saliba R., et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 107 (2006) 3074-3080
34. Flowers M.E., Apperley J.F., van Besien K., et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 112 (2008) 2667-2674
35. Akpek G., Lee S.M., Anders V., and Vogelsang G.B. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease. Biol Blood Marrow Transplant 7 (2001) 495-502
36. Jacobsohn D.A., Chen A.R., Zahurak M., et al. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. J Clin Oncol 25 (2007) 4255-4261
37. Gilman A.L., Chan K.W., Mogul A., et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 6 (2000) 327-334
38. Hockenbery D.M., Cruickshank S., Rodell T.C., et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 109 (2007) 4557-4563
39. Parker P.M., Chao N., Nademanee A., et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 86 (1995) 3604-3609
40. Lopez F., Parker P., Nademanee A., et al. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 11 (2005) 307-313
41. Mookerjee B., Altomonte V., and Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant 24 (1999) 517-520
42. Ratanatharathorn V., Carson E., Reynolds C., et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 133 (2000) 275-279
43. Jurado M., Vallejo C., Perez-Simon J.A., et al. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant 13 (2007) 701-706
44. Browne P.V., Weisdorf D.J., DeFor T., et al. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant 26 (2000) 865-869
45. Brochu S., Rioux-Masse B., Roy J., Roy D.C., and Perreault C. Massive activation-induced cell death of alloreactive T cells with apoptosis of bystander postthymic T cells prevents immune reconstitution in mice with graft-versus-host disease. Blood 94 (1999) 390-400
46. Chung B., Dudl E., Toyama A., Barsky I., and Weinberg K.I. Importance of interleukin-7 in the development of experimental graft-versus-host disease. Biol Blood Marrow Transplant 14 1 (2008) 16-27
47. Chung B., Dudl E.P., Min D., Barsky L., Smiley N., and Weinberg K.I. Prevention of graft-versus-host disease by anti IL-7Ralpha antibody. Blood 110 8 (2007) 2803-2810
48. Dean R.M., Fry T.J., Mackall C.L., et al. Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. J Clin Oncol (2008) in press
49. Dulude G., Roy D.C., and Perreault C. The effect of graft-versus-host disease on T cell production and homeostasis. J Exp Med 189 (1999) 1329-1342
50. Gorski J., Chen X., Gendelman M., et al. Homeostatic expansion and repertoire regeneration of donor T cells during graft versus host disease is constrained by the host environment. Blood 109 (2007) 5502-5510
51. Fagnoni F.F., Oliviero B., Giorgiani G., et al. Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after allogeneic myeloablative hematopoietic stem cell transplantation. Blood 104 (2004) 281-289
52. Arpinati M., Chirumbolo G., Urbini B., et al. Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 10 (2004) 106-115
53. Giraud S., Dhedin N., Gary-Gouy H., Lebon P., Vernant J.P., and Dalloul A. Plasmacytoid dendritic cell reconstitution following bone marrow transplantation: subnormal recovery and functional deficit of IFN-alpha/beta production in response to herpes simplex virus. J Interferon Cytokine Res 25 (2005) 135-143
54. Mohty M., Blaise D., Faucher C., et al. Impact of plasmacytoid dendritic cells on outcome after reduced-intensity conditioning allogeneic stem cell transplantation. Leukemia 19 (2005) 1-6
55. Rajasekar R., Mathews V., Lakshmi K.M., et al. Plasmacytoid dendritic cell count on day 28 in HLA-matched related allogeneic peripheral blood stem cell transplant predicts the incidence of acute and chronic GVHD. Biol Blood Marrow Transplant 14 (2008) 344-350
56. Vakkila J., Thomson A.W., Hovi L., Vettenranta K., and Saarinen-Pihkala U.M. Circulating dendritic cell subset levels after allogeneic stem cell transplantation in children correlate with time post transplant and severity of acute graft-versus-host disease. Bone Marrow Transplant 35 (2005) 501-507